Why do patients with atrial fibrillation not receive warfarin?

By T. Bungard, W. Ghali, K. Teo, F. McAlister, R. Tsuyuki. Archives of Internal Medicine, 2000

630 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Economics and Econometrics, Epidemiology

View Paper: https://www.semanticscholar.org/paper/12b6eef395f0cb963ecd77061c6764ceece12739

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Halperin

In Economics and Econometrics

1. Saibal Kar

Citations in the corpus

• Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. (2014, background): “Goar (El Camino Hospital, Mountain View, California [2]); Richard Josephson (Summa Health System, Akron, Ohio [2]); W.”
• Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial (2013, background): “Systemic anticoagulant drug therapy is highly effective but difficult for many patients to sustain over time, which has led to an intensive quest for alternative strategies, especially for patients at highest risk.(4,5) Nonpharmacological approaches are under development to isolate the left atrial a”
• 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. (2017, background): “But excluding procedure-related events, consistent with the absence of chronic OAC treatment, LAAC patients experienced substantially fewer major bleeds (HR: 0.48; 95% CI: 0.32 to 0.71; p ¼ 0.0003).”